Answers are grounded in this paper and cite their sources.
Demonstrates that CAR peptide co-administration enhances fasudil-induced pulmonary pressure reduction in swine, indicating improved pulmonary vascular selectivity.
Introduction and Objectives . Despite the approval of several medications for pulmonary hypertension, morbidity and mortality are unacceptably high. Systemic hypotension may limit the use of pulmonary hypertension medications. The aim of this study was to assess whether the homing peptide CAR (CARSKNKDC) improved the vasodilatory selectivity of fasudil on the pulmonary circulation vs the systemic circulation in a porcine pulmonary hypertension model. Materials and Methods . Pulmonary hypertension (to approximately 2/3-3/4 systemic pressure levels) was induced by chronic and acute administration of microspheres in 3 micro Yucatan pigs (mean weight 19.9 kg, mean age 4.3 months). Fasudil (0.3 mg/kg) was administered without and with CAR (1.5 mg/kg) and the effects on aortic (Ao) and right ventricular (RV) pressure was recorded with indwelling catheters. Results . Immediately after fasudil administration, there was a decrease in Ao pressure followed by prompt recovery to baseline. The RV pressure decrease was progressive and sustained. Fasudil alone resulted in a 12 % decrease in RV pressure, whereas the co-administration of CAR with fasudil resulted in a 22 % decrease in RV pressure (p < 0.0001). Fasudil alone caused an average decrease of 34% in the RV/Ao pressure ratio and fasudil + CAR caused an average decrease of 40% in the RV/Ao pressure ratio (p < 0.0001). Conclusion . The homing peptide CAR selectively enhances the acute vasodilatory effects of fasudil on the pulmonary vascular bed in a porcine experimental model of pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Rothman et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: